AtriCure, Inc. (ATRC) Stock Price & Analysis
AtriCure, Inc. (ATRC) closed at USD 59.3 on Thursday, October 22, 2026, up 2.83% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 57.67; the Oct 22, 2026 session ranged USD 57.76–59.54 on volume of 498,176 shares. Market capitalization is $3.02B, with a 52-week range of USD 25.36–61.7 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ATRC.md
Key facts (ATRC)
- Last four reported quarters (through Jun 30, 2026): revenue $570M, net income $10.6M (1.9% margin), free cash flow $53.1M (SEC filings).
- Valuation: P/E 285.9x.
- 1 of 80 tracked superinvestors hold ATRC (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (10 analysts), mean target USD 57.56 (range 36–68).
- Total return with dividends: 1Y +58.6% vs S&P 500 +14.9%; 5Y -18.9% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.01, revenue estimate $151M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ATRC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $274M | $330M | $399M | $465M | $535M | $570M |
| Gross profit | $206M | $246M | $300M | $348M | $401M | — |
| Operating income | $55.2M | -$42.7M | -$26.7M | -$40.0M | -$9.4M | $12.9M |
| Net income | $50.2M | -$46.5M | -$30.4M | -$44.7M | -$11.4M | $10.6M |
| EPS (diluted) | $1.09 | -$1.02 | -$0.66 | -$0.95 | -$0.24 | — |
| Free cash flow | -$23.5M | -$39.0M | -$7.5M | $745K | $48.3M | $53.1M |
| Gross margin | 75.0% | 74.4% | 75.2% | 74.7% | 75.0% | — |
| Operating margin | 20.1% | -12.9% | -6.7% | -8.6% | -1.8% | 2.3% |
| Net margin | 18.3% | -14.1% | -7.6% | -9.6% | -2.1% | 1.9% |
| Revenue growth | +32.8% | +20.4% | +20.8% | +16.5% | +14.9% | — |
| Cash + short-term investments | $119M | $121M | $137M | $123M | — | — |
| Total debt | $60.0M | $60.0M | $60.6M | $61.9M | $61.9M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ATRC)
P/E 285.9x · P/S 5.3x · P/FCF 56.8x · P/B 5.8x · FCF yield 1.76% · Earnings yield 0.35%
Superinvestors (SEC 13F-HR, Q2 2026) (ATRC)
1 of 80 tracked investors hold ATRC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.01% | $8.3M | Added +13.5% |
Analysts (ATRC)
Consensus Buy (mean 2.00 on a 1–5 scale), 10 analysts; mean target USD 57.56 (low 36, high 68).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Citizens | Target raised | Market Outperform | $52 → $68 |
| 2026-10-12 | BTIG | Target raised | Buy | $55 → $63 |
| 2026-10-02 | Freedom Capital Markets | Downgrade | Buy → Hold | $43 → $57 |
| 2026-09-02 | Needham | Target raised | Buy | $45 → $64 |
| 2026-08-27 | Piper Sandler | Target raised | Overweight | $50 → $60 |
| 2026-08-24 | BTIG | Target raised | Buy | $45 → $55 |
| 2026-07-28 | UBS | Target lowered | Buy | $55 → $50 |
Total return (dividends reinvested) (ATRC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +58.6% | -18.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +58.9% | -4.1% |
| Volatility (annualized) | 46.6% | 46.0% |
| Max drawdown | -39.0% (Jan 2026→Jun 2026) | -76.2% (Nov 2021→Jun 2024) |
ATRC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.01 | $0.02 | -22.1% | $151.2M | 9 |
| Next quarter (ends Dec 2026) | $0.09 | $0.08 | +6.7% | $160.2M | 9 |
| Current fiscal year (ends Dec 2026) | $0.28 | $0.12 | +133.3% | $606.3M | 9 |
| Next fiscal year (ends Dec 2027) | $0.43 | $0.35 | +24.5% | $680.2M | 9 |
ATRC options: expected move
Options price a move of about ±13.0% (±$7.70) by Nov 20, 2026, which includes earnings on Nov 3, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 57.4% | ±13.0% |
| Dec 18, 2026 | 56 | 48.2% | ±15.2% |
| Jan 15, 2027 | 84 | 44.4% | ±17.0% |
| Apr 16, 2027 | 175 | 48.0% | ±25.7% |
30-day implied volatility 46.2% vs 40.8% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 59.3 |
|---|---|
| Change | ▲ 2.83% (up) |
| Previous Close | USD 57.67 |
| Open | USD 57.76 |
| Day Range | USD 57.76 – 59.54 |
| 52-Week Range | USD 25.36 – 61.7 |
| Volume | 498,176 shares |
| Market Cap | $3.02B |
| Exchange | NGM |
Technical Analysis (ATRC)
Nexqual's technical model rates ATRC "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.88 (neutral) |
| vs SMA50 | Above (USD 53.72) |
| MACD | 1.12 (positive) |
Analyst Ratings (ATRC)
Wall Street analysts rate ATRC "Buy" based on 10 analysts, with a mean price target of USD 57.56 (range USD 36–68), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 57.56 |
| High Target | USD 68 |
| Low Target | USD 36 |
| Buy / Hold / Sell | 7 / 3 / 0 |
Earnings (ATRC)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.01 |
| Revenue Estimate | $151.19M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.18 vs est 0.02 ▲ beat |
| 2026-03-31 | USD 0 vs est -0.06 ▲ beat |
| 2025-12-31 | USD 0.06 vs est -0.04 ▲ beat |
| 2025-09-30 | USD -0.01 vs est -0.12 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (ATRC)
| Total Revenue | $569.62M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +12.80% |
| Gross Margin | +76.30% |
| Operating Margin | +6.29% |
| Profit Margin | +1.85% |
| ROE | +2.15% |
| Debt / Equity | 0.14 |
| Current Ratio | 4.22 |
| Total Cash | $167.79M |
| Total Debt | $74.22M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $53.11M (9.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (ATRC)
Nexqual rates AtriCure, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Solid — Revenue +15% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 76%, operating 6% (last 12 months) |
| Balance Sheet | Strong — $168M cash vs $74M debt, net cash position |
| Cash Flow | Solid — FCF $53M (last 4 quarters to Jun 2026, SEC), 9% margin |
| Efficiency | Weak — ROE 2%, ROA 1.3% |
Ownership (ATRC)
| Insider Ownership | +3.76% |
|---|---|
| Institutional Ownership | +105.52% |
| Shares Outstanding | 50.87M |
| Float | 48.83M |
| Short % of Float | +9.86% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Leadership (ATRC)
AtriCure, Inc. is led by Michael H. Carrel, CEO, President & Director, per Nexqual as of October 23, 2026 at 09:24 UTC.
| CEO, President & Director | Michael H. Carrel |
|---|---|
| Chief Financial Officer | Angela L. Wirick |
| Chief Operating Officer | Douglas J. Seith |
| Chief Marketing & Strategy Officer | Justin J. Noznesky |
| Chief Scientific Officer | Vinayak Doraiswamy |
Major Backers & Investors (ATRC)
Notable institutional backers of AtriCure, Inc. include Wellington Management, Hood River Capital Management LLC, Alliancebernstein L.P., according to Nexqual as of October 23, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 6.87% |
| Hood River Capital Management LLC | 5.71% |
| Alliancebernstein L.P. | 5.44% |
| Nomura Asset Management International Inc | 3.41% |
| Goldman Sachs | 3.14% |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 3% |
| Marshall Wace LLP | 2.62% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 10.46% |
| BlackRock | 8.8% |
| State Street | 2.73% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WRBY | Warby Parker Inc. | USD 25.67 | ▲ 0.16% |
| PLSE | Pulse Biosciences, Inc | USD 52.68 | ▲ 2.67% |
| NVST | Envista Holdings Corporation | USD 23.97 | ▲ 3.36% |
| ICUI | ICU Medical, Inc. | USD 168.33 | ▲ 4.66% |
| LMAT | LeMaitre Vascular, Inc. | USD 85.33 | ▲ 1.98% |
| XRAY | DENTSPLY SIRONA Inc. | USD 9.5 | ▲ 4.63% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt